

# Graves' Ophthalmopathy - Pipeline Insight, 2019

<https://marketpublishers.com/r/G3151E2E75BEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: G3151E2E75BEN

## Abstracts

This report can be delivered to the clients within 24 Hours

"Graves' Ophthalmopathy - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves' Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves' Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves' Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves' Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Graves' Ophthalmopathy Understanding

Graves' Ophthalmopathy also known as Graves' eye disease or Graves' Orbitopathy is a problem that usually develops in people with an overactive thyroid caused by Graves' disease. It is an autoimmune condition where the body's immune system produces an antibody to cells in the thyroid gland causing an overproduction of thyroid hormones. It appears that the same antibody that can cause thyroid dysfunction may also have an "attraction" to tissues surrounding the eyes causing the onset of Graves' Ophthalmopathy. The disease is categorized as mild, moderate, and severe. Some common symptoms of Graves' Ophthalmopathy includes, feeling of irritation or grittiness in the eyes, redness or inflammation of the conjunctiva (the white part of the eyeball), excessive tearing or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision. In more advanced eye disease there may also be decreased eye movement and eyelids, incomplete closure of the eye with corneal ulceration, compression of the optic nerve

and rarely, loss of vision.

### Graves' Ophthalmopathy Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Graves' Ophthalmopathy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Graves' Ophthalmopathy pipeline report covers 6+ companies. Some of the key players include HanAll Biopharma (HL 161), Horizon Therapeutics (Teprotumumab) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

### Graves' Ophthalmopathy Analytical Perspective by DelveInsight

#### In-depth Graves' Ophthalmopathy Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

#### Graves' Ophthalmopathy Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

### **Scope of the report**

The Graves' Ophthalmopathy report provides an overview of therapeutic

pipeline activity for Graves' Ophthalmopathy across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Graves' Ophthalmopathy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Graves' Ophthalmopathy Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Graves' Ophthalmopathy

## **Reasons to Buy**

Establish a comprehensive understanding of the current pipeline scenario across Graves' Ophthalmopathy to formulate effective R&D strategies

Assess challenges and opportunities that influence Graves' Ophthalmopathy R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Graves' Ophthalmopathy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Graves' Ophthalmopathy to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

## Contents

### 1. REPORT INTRODUCTION

### 2. GRAVES' OPHTHALMOPATHY

- 2.1. Graves' Ophthalmopathy Disease Overview
- 2.2. Graves' Ophthalmopathy History
- 2.3. Graves' Ophthalmopathy Symptoms
- 2.4. Graves' Ophthalmopathy Causes
- 2.5. Graves' Ophthalmopathy Pathophysiology
- 2.6. Graves' Ophthalmopathy Diagnosis
  - 2.6.1. Diagnostic Guidelines

### 3. GRAVES' OPHTHALMOPATHY CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

### 4. GRAVES' OPHTHALMOPATHY- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
  - 4.1.1. Graves' Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
    - 4.1.1.1. Assessment Summary
  - 4.1.2. Graves' Ophthalmopathy Collaboration Deals
    - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.2. Graves' Ophthalmopathy Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
  - 4.2.1. Assessment by Phase of Development
  - 4.2.2. Assessment by Product Type (Mono / Combination)
    - 4.2.2.1. Assessment by Stage and Product Type
  - 4.2.3. Assessment by Route of Administration
    - 4.2.3.1. Assessment by Stage and Route of Administration
  - 4.2.4. Assessment by Molecule Type
    - 4.2.4.1. Assessment by Stage and Molecule Type
  - 4.2.5. Assessment by MOA
    - 4.2.5.1. Assessment by Stage and MOA

## **5. GRAVES' OPHTHALMOPATHY PIPELINE THERAPEUTICS**

- 5.1. Late Stage Products (Phase-III)
  - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
  - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
  - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
  - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

## **6. GRAVES' OPHTHALMOPATHY-PRODUCTS ANALYSIS**

- 6.1. Product Profiles
  - 6.1.1. HL 161- HanAll Biopharma
    - 6.1.1.1. Product Description
      - 6.1.1.1.1. Product Overview
      - 6.1.1.1.2. Mechanism of Action
    - 6.1.1.2. Research and Development
      - 6.1.1.2.1. Clinical Studies
        - 6.1.1.2.1.1. Detailed Study Description
        - 6.1.1.2.1.2. Study Results
        - 6.1.1.2.1.3. Clinical Trials: Tabular View
    - 6.1.1.3. Product Development Activities
      - 6.1.1.3.1. Tabulated Product Summary
        - 6.1.1.3.1.1. General Description Table
  - 6.1.2. Teprotumumab- Horizon Therapeutics
    - 6.1.2.1. Product Description
      - 6.1.2.1.1. Product Overview
      - 6.1.2.1.2. Mechanism of Action
    - 6.1.2.2. Research and Development
      - 6.1.2.2.1. Clinical Studies
        - 6.1.2.2.1.1. Detailed Study Description
        - 6.1.2.2.1.2. Study Results
        - 6.1.2.2.1.3. Clinical Trials: Tabular View
    - 6.1.2.3. Product Development Activities
      - 6.1.2.3.1. Tabulated Product Summary
        - 6.1.2.3.1.1. General Description Table

To be continued in the report.....

## **7. RECENT TECHNOLOGIES**

## **8. GRAVES' OPHTHALMOPATHY KEY COMPANIES**

- 8.1. BTG
- 8.2. Horizon Therapeutics
- 8.3. HanAll Biopharma
- 8.4. Enceladus Pharmaceuticals
- 8.5. Pfizer
- 8.6. Shanghai Henlius Biotech

## **9. GRAVES' OPHTHALMOPATHY KEY PRODUCTS**

- 9.1. Otelixizumab
- 9.2. Teprotumumab
- 9.3. HL 161
- 9.4. Liposome encapsulated prednisolone
- 9.5. Celecoxib
- 9.6. Rituximab biosimilar

## **10. DORMANT AND DISCONTINUED PRODUCTS**

- 10.1. Dormant Products
  - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
  - 10.2.1. Reasons for the discontinuation

## **11. GRAVES' OPHTHALMOPATHY- UNMET NEEDS**

## **12. GRAVES' OPHTHALMOPATHY- FUTURE PERSPECTIVES**

## **13. APPENDIX**

## **14. REPORT METHODOLOGY**

- 14.1. Secondary Research
- 14.2. Expert Panel Validation





## List Of Tables

### LIST OF TABLES

- Table 1. Graves' Ophthalmopathy Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Graves' Ophthalmopathy Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Graves' Ophthalmopathy companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Graves' Ophthalmopathy Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

### KEY COMPANIES

BTG  
Horizon Therapeutics  
HanAll Biopharma  
Yuhan

Enceladus Pharmaceuticals  
Pfizer  
Shanghai Henlius Biotech

## I would like to order

Product name: Graves' Ophthalmopathy - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/G3151E2E75BEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3151E2E75BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970